Infectious Disease Care
qPCR vs. Culture Testing
CUUR Diagnostics
Topic: qPCR vs. Culture Testing
Our Infectious Disease Diagnostic Goal:
Improving Patient Outcomes with qPCR

For decades, infectious diseases have caused significant public health and financial challenges. Traditionally, routine laboratory testing for infectious agents is performed with culture-based methods, which have a low sensitivity and specificity and can take days to get results. 

Infectious Diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites, or fungi, which can directly or indirectly spread
from one person to another. The impact of these pathologies is evidenced by: 

  • High numbers of individuals impacted by Infectious Disease 
  • Lack of knowledge about the infectious agents 
  • Global socioeconomic impact of Infectious Disease 
  • Advent of Antimicrobial Resistance 
  • Increase in molecular diagnostic research for Infectious Disease 
  • Rapid developments of diagnostic techniques for the early detection 
  • Emergence of new infectious diseases 
  • Reemergence of diseases once controlled 
  • Development of Diagnostic and Antimicrobial Stewardship 


  • Highest level of sensitivity and specificity (99.999%)
  • Can be completed in 24-hours 
  • Simultaneously identifies viruses, bacteria, parasites, and fungi 
  • Provides a more definitive diagnosis 
  • Current antibiotic use does not affect results


  • Involves high level of trial and error 
  • Lengthy waiting periods 
  • Potential to fail to identify organisms 
  • Requires costly lab time 
  • Analysis is affected by current antibiotic use

Culture Method: Long turn-around times to detect pathogens by conventional culture methods is insufficient to rapidly diagnose infectious diseases. Not all pathogens are cultivable and may require discernment of species, virulence factors, and antimicrobial resistance to be effective. In contrast, the amplification techniques in molecular testing can be used for detection, genotyping, and quantification of virus and bacteria in various clinical specimen types.

qPCR: Rapid Results with Extreme Specificity to Improve Patient Outcomes

Molecular diagnostics can identify a wide range of microorganisms. Due to its incredible sensitivity, specificity, reproducibility, broad dynamic range, and
speed of amplification qPCR has been championed by infectious disease experts for identifying organisms that cannot be grown in vitro or where existing culture techniques are insensitive or require prolonged incubation times. Advances in development of molecular technology and diagnostics have enhanced understanding Infectious Disease etiology, pathogenesis, and molecular epidemiology. Molecular diagnostics provide a basis for quantification, appropriate detection, prevention, and control measures by which some diseases have been successfully eliminated.

According to the World Health Organization, the CoVs are a large family of single-stranded RNA viruses (+ssRNA) and are enveloped viruses with nucleocapsid. 

CUUR Diagnostics’s molecular qPCR laboratories are specifically suited to detect and diagnose the CORONAVIRUS (COVID-19). 

Our laboratory testing provides superior sensitivity and specificity to identify pathogens, such as COVID-19, using qPCR DNA and RNA level sequencing, resulting in extreme accuracy and diagnosis within hours.

We utilize industry leading equipment including the latest technologies from ThermoFisher and have earned the FDA’s Emergency Use Authorization (EUA) status. Additionally, CUUR Diagnostics holds both CAP and CLIA accreditations.

CUUR Diagnostics is a biotechnology company focused on improving patient, provider and facility healthcare outcomes for Infectious Disease. Our advanced, proprietary solution combines technology, diagnostics, data management, decision platforms and outcomes analysis utilizing Artificial Intelligence (AI). With the largest data set of Infectious Disease targets available in the world, CUUR Diagnostics offers tremendous flexibility, extremely precise diagnosis, treatment guidance for patients and improved antibiotic stewardship. 

qPCR – Better Approach than Classical Diagnostics

  • High Specificity: Reports precisely which microbes are present
  • High Sensitivity: Improved detection rates over classical culture, microscopy and clinical evaluations
  • Broad Coverage: Comprehensive tests cover multiple microrganisms from five major target types: bacteria, virus, yeast, protozoa, and mycoplasma/ureaplasma
  • Panel Testing: Specific panels can be run individually for pathogen identification or together as a comprehensive screen for reflex determination of antibiotic resistance susceptibility for certain pathogenic targets
  • Single Sample: Requires only a single patient sample collection 


  • Real-time PCR uses robust 5’ nuclease chemistry
  • Small amount of input DNA required
  • High sensitivity and specificity
  • All assays pre-designed and validated
  • Low cost per sample
  • Reproducible and empirical
  • Easy workflow with rapid, accurate throughput
  • Survey multiple pathogens from single sample
  • Quantitative results enable comparisons between different samples and with clinical criteria
  • Objective scoring, does not require subjective expertise as seen with microscopy
  • Identify organisms associated with more than one condition
Infectious Disease Care
Infectious Disease Care

CUUR Diagnostics is a biotechnology company focused on improving patient, provider and facility healthcare outcomes for Infectious Disease. Learn More.


Ask your physician for the CUUR Box. The easy 1,2,3 of sample testing – Swap, Pack, Ship. Over 97% of tests returned in 24-48 of hours from receipt. Learn More.


CuurCloud is a robust laboratory information management system and provider/patient portal that supports the infectious disease diagnostics efforts of CUUR Diagnostics and its customers. Learn More.

Infectious Disease Care
Learn More Important Information About CUUR Diagnostics by Visiting Our Main Site.

CUUR Diagnostics was founded by experienced medical scientists and healthcare professionals and utilize industry leading equipment including Thermofisher, under CAP and CLIA quality standards, to rapidly deliver high complexity qPCR molecular testing for infectious disease identification. The CUUR Diagnostics’ SARS-COV-2 assay is an Emergency Use Authorization (EUA) test awarded by the U.S. FDA.

CUUR Diagnostics is a division of Assurity Healthcare, a Medicare-certified clinical laboratory provider that offers innovative healthcare laboratory solutions to hospitals, clinics and other medical entities. Serving clients across multiple states in the U.S., our services include infectious disease testing, planning, build-out, staffing, compliance and operation of complex medical labs.

CUUR Panels:
Respiratory w/COVID-19, UTI, Skin & Wound, Vaginal Microbiota, Nail, STI, Gastrointestinal, Antimicrobial Resistance, and Custom Panels


Stay in Touch

Don’t Miss A Beat! Learn Valuable Viewpoints About Today’s Infectious Disease Issues